Objective: Varicella-zoster virus (VZV) infection may trigger the inflammatory cascade that characterizes giant cell arteritis (GCA).
Further studies detected VZV antigen in 5/24 (21%) GCA-negative TAs. 5 Subsequently, a GCA-negative TA was found to contain VZV antigen and VZV DNA in multiple regions (skip areas); examination of additional sections adjacent to those containing VZV antigen revealed classic GCA pathology, resulting in a change of diagnosis from GCAnegative to GCA-positive. 6 Finally, VZV antigen and VZV DNA were found in multiple noncontiguous (skip) areas in the TA of a patient with clinical GCA and ipsilateral ophthalmic-distribution zoster, followed 2 weeks later by VZV encephalitis and 2 months later by ischemic optic neuropathy, but whose TA was pathologically negative for GCA. 7 The repeated detection of VZV in multiple GCAnegative TAs as well as in a GCA-positive TA prompted virologic analysis of TA biopsies from patients with pathologically confirmed GCA and control TAs removed at autopsy from adults . age 50 to test for a causal link between VZV and GCA. METHODS Immunohistochemical analysis of human temporal arteries for VZV antigen. One hundred 5-mm sections of all FFPE TAs were cut and baked for 1 hour at 60°C. Every other section (50 slide sections/TA) was then deparaffinized and immunostained with a 1:500 dilution of mouse monoclonal anti-VZV glycoprotein E (gE) IgG1 antibody (Santa Cruz Biotechnology, Dallas, TX) for 2 hours, followed by a 1:1,000 dilution of secondary biotinylated goat anti-mouse antibody (Dako, Carpinteria, CA) for 1 hour and prediluted streptavidin-alkaline phosphatase (BD Biosciences, San Diego, CA) for 1 hour. All incubations were at room temperature. The color reaction was developed under a light microscope using the fresh fuchsin substrate system (Dako) with levamisole (Dako; 24 mg/mL), as described. 5 Slides were counterstained with 13 hematoxylin for 2 minutes. When a section was found to contain VZV antigen, at least 2 adjacent sections were stained as above except that mouse anti-VZV gE IgG1 antibody was replaced with a 1:500 dilution of control mouse IgG1 antibody (Dako). To confirm the specificity of VZV antigen detection, some TAs that contained VZV antigen were also stained with 2 different anti-VZV antibodies: (1) 1:10,000 dilution rabbit anti-VZV IE63 antibody, and (2) a different mouse anti-VZV gE antibody directed against amino acids 150-162. 8 Two negative controls for rabbit anti-VZV IE63 antibody were provided by replacing the rabbit anti-VZV IE63 antibody with either normal rabbit serum or rabbit anti-herpes simplex virus (HSV)-1 antibody (Dako). Positive controls consisted of VZVinfected cadaveric cerebral and temporal arteries maintained for 14 days in vitro and then stained with mouse anti-VZV gE IgG1 antibody as described above.
Using light microscopy, 2 readers (D.G. and M.A.N.) blinded to the diagnosis of GCA-positive or normal TA examined each section. A TA section was deemed positive or negative for VZV antigen only when both readers agreed; the readers disagreed about 4/86 GCA-positive TAs and 3/16 normal TAs, and those 7 TAs were excluded from the study. The distribution of VZV antigen and number of skip lesions, defined as at least 2 VZV antigen-positive regions flanked by VZV antigen-negative regions, were then assessed.
Histopathologic analysis of sections adjacent to those containing VZV antigen for pathologic features of GCA.
For each section that contained VZV antigen, an adjacent section (within 5 mm) was stained with hematoxylin and eosin. Slides were examined by standard light microscopy by the neuropathologist (P.J.B.) and neurovirologists (D.G. and M.A.N.) for GCA positivity, defined based on the presence of medial damage, medial inflammation, and giant or epithelioid cells. A TA section was deemed GCA-positive only when all readers agreed that all 3 criteria were met.
PCR amplification of VZV DNA in temporal artery sections containing VZV antigen. Every section of 61 VZV antigen-positive TAs was scraped with a scalpel, pooled, placed into 200 mL lysis buffer with proteinase K, and incubated overnight at 56°C (DNeasy Blood and Tissue Kit; Qiagen, Germantown, MD). DNA was extracted per the manufacturer's protocol and eluted in 50 mL water. Quantitative PCR analysis with primers for VZV and for glyceraldehyde-3-phosphatedehydrogenase (GAPdH) was performed on 5 mL, as described. 7 Similarly, every VZV antigen-positive section of skeletal muscle adjacent to a TA was scraped and treated as described above to detect amplifiable VZV DNA by real-time quantitative PCR. Samples were considered positive for VZV DNA if (1) no VZV DNA amplification was detected in samples without added DNA, (2) GAPdH was detected in wells with TA DNA, and (3) at least 2 of 4 PCR replicates amplified at least 10 copies of target VZV DNA per 5 mL of DNA extracted. VZV DNA copy number was determined using known concentrations of VZV DNA as PCR standards. 9 Ultrastructural examination. Immunofluorescent staining with mouse monoclonal antibody (Mab 3B3) directed against VZV gE was used as described 8 to locate foci of VZV infection. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) were then used to identify viral particles, as described. 10 VZV antigen in skeletal muscle adjacent to infected temporal arteries. Skeletal muscle was found in 39/82 (48%) GCA-positive TAs. Among the 61 GCApositive TAs that contained VZV antigen, 32 (52%) also contained muscle, and VZV antigen was found in 12/32 (38%) of these samples (figure 1, R and X).
VZV DNA in temporal arteries. Of the 61 GCApositive TAs that contained VZV antigen, only 45 contained amplifiable cellular DNA. Of these 45 TAs, 18 (40%) contained VZV DNA. VZV DNA was also detected in one normal TA in which VZV antigen was found in 12 skip areas. Of the 12 skeletal muscles that contained VZV antigen, 10 contained amplifiable cellular DNA. Of these 10 skeletal muscles, 6 (60%) contained VZV DNA. In 27 GCA-positive TAs and 4 skeletal muscles, all of which contained VZV antigen and amplifiable cellular DNA, VZV DNA was not detected. This is most likely due to formalin fixation, which reduces the abundance of amplifiable DNA; furthermore, the number of VZV antigen-positive slides from which DNA was extracted was often low.
Association of histopathologic changes with VZV antigen in temporal arteries. In GCA-positive TAs, histopathologic analysis of sections adjacent to those containing VZV antigen revealed GCA pathology in 248/279 (89%) sections (figure 3; 95% CI 86%, 93%), whereas the 18 sections adjacent to 12 skip areas in the one normal TA that contained VZV antigen showed no areas of GCA pathology (0%; 95% CI 0%, 19%). The difference in pathology proportions was highly significant (p , 0$0001, Fisher exact association test). DISCUSSION Herein we report findings from the immunohistochemical analysis of 4,100 sections from 82 pathologically verified GCA-positive TAs (50 slides/TA). Using an anti-VZV IgG1 antibody directed against VZV gE that is found only in productively infected cells, immunohistochemical analysis detected VZV antigen in 61/82 (74%) GCA-positive TAs, while PCR amplified VZV DNA (despite formalin fixation) in 18/45 (40%) VZV antigen-positive TAs that contained amplifiable cellular DNA. Both TEM and SEM revealed varicella-zoster virions in VZV antigenpositive areas. The relevance of VZV in GCApositive TAs was further shown by (1) the presence of VZV in skip areas, paralleling a characteristic feature of GCA pathology; (2) the close proximity of VZV antigen in TAs with adjacent GCA pathology; and (3) the presence of VZV antigen and VZV DNA in skeletal muscle adjacent to VZV antigen-positive TAs. Because all subjects were deidentified except for age and sex, no clinico-virologic correlations could be made regarding the presence of VZV in GCA-positive TAs and a history of zoster, zoster vaccination, or medication.
VZV antigen was found in cells in the adventitia, media, and intima of TAs, consistent with the welldocumented ability of VZV to replicate in all organs during disseminated varicella and zoster as well as in all human non-neuronal cells in tissue culture. The similar distribution of VZV antigen predominantly in the arterial adventitia, slightly less in the media, and least in the intima in both GCA-positive TAs and intracerebral VZV vasculopathy 12 indicates that the mechanism by which VZV infects arteries after reactivation from cranial nerve ganglia is transaxonal spread to arteries, initially infecting the adventitia followed by extension transmurally. Such a mechanism is further supported by our detection of varicellazoster virions in the adventitia of a GCA-positive TA.
The presence of VZV antigen in GCA lesions is not likely to be a bystander effect due to subclinical reactivation induced by inflammation. After more than 3 decades of analysis of tissue sections for VZV from patients with inflammatory/infectious diseases, we found that while VZV causes inflammation, inflammation does not cause VZV to reactivate and infect the inflamed region. We have never found VZV in inflammatory brain tissue 13 or in highly inflammatory CSF in patients with meningitis. 14 VZV is only associated with inflammation when VZV causes the inflammatory response, as exemplified by our demonstrations of VZV in intracerebral arteries of patients with VZV vasculopathy 15 and our recent demonstration of VZV antigen and VZV DNA in a patient with VZV pneumonitis, giant cells, and Cowdry A inclusions. 16 A close association of GCA with intracerebral VZV vasculopathy was also revealed by in situ hybridization, which detected VZV DNA in a GCA-positive TA from a patient who developed bilateral internuclear ophthalmoplegia and right middle cerebral artery stroke 2 months after ophthalmic-distribution zoster, 17 and by immunohistochemical detection of VZV antigen in a GCA-positive TA from a patient who developed choroidal infarction 4 months after ophthalmic-distribution zoster. 18 Together, the collective clinical, pathologic, and virologic findings indicate that GCA is essentially a VZV vasculopathy primarily affecting the TA.
It is not surprising that skeletal muscle adjacent to VZV-infected TAs is infected with VZV, since the No staining was seen in sections adjacent to those containing VZV antigen when mouse isotype IgG1 antibody was substituted for mouse anti-VZV gE IgG1 antibody (G-J) or when normal rabbit serum was substituted for rabbit anti-VZV antibody (K, L). Discontinuous skip areas containing VZV antigen in a TA that was pathologically positive for GCA were shown by immunohistochemical staining with mouse anti-VZV gE IgG1 antibody as described in the Methods. VZV antigen was seen at positions 125-130 mm (M), 215-220 mm (O), and 255-260 mm (Q), but not at intervening regions at positions 131-214 mm (N) and 221-254 mm (P). Sections adjacent to those shown in panels M-Q were negative after immunostaining with mouse isotype IgG1 antibody (S-W). VZV antigen was often seen in skeletal muscle adjacent to a VZV-infected TA immunostained with mouse anti-VZV gE IgG1 antibody (R) that was not seen with mouse IgG1 antibody (X). 6003 magnification.
Figure 2
Immunofluorescent staining and ultrastructural imaging of VZV-infected temporal artery A giant cell arteritis-positive temporal artery (A) was examined for the presence of varicella-zoster virus (VZV) antigen in the adventitia (a), media (m), and intima (i). Immunohistochemical staining with rabbit anti-VZV IE63 antibody revealed VZV antigen in the media (B, pink color), but not after staining with rabbit anti-herpes simplex virus-1 antibody (C). Immunofluorescent staining with a different mouse anti-VZV IgG antibody than that used for immunohistochemistry in figure 1 revealed VZV antigen in the adventitia (D, red color), but not when primary antibody was omitted (E). Sections adjacent to those containing VZV antigen were prepared for transmission electron microscopy (TEM) and scanning electron microscopy (SEM) as described in the Methods. TEM revealed an enveloped virus particle (F, arrow), and SEM showed a cluster of virus particles in the adventitia egressing through an outer cell wall (G, arrows). Viral particles appear slightly larger than 200 nm because they were sputter coated with a gold alloy. In panels F and G, scale bars 5 300 nm. EM 5 electron microscopy.
mammalian superficial TA is richly innervated 19 and nociception in connective tissue of the temporalis muscle is relayed by afferent fibers with cell bodies in the trigeminal ganglia 20,21 from which VZV reactivates.
A comparison of the presence of VZV in GCApositive TAs and normal TAs obtained from individuals over age 50 (when GCA usually develops) revealed important differences. VZV was present in only 1/13 normal TAs, and even though VZV antigen was found in 12 skip areas, histopathologic analysis revealed no GCA pathology in any of 18 sections adjacent to those containing VZV antigen. In contrast, histopathologic analysis of 279 sections adjacent to those containing VZV antigen in GCA-positive TAs revealed GCA pathology in 248 (89%) sections, confirming the close relationship between GCA pathology and the presence of VZV antigen. The presence of VZV in one normal TA most likely indicated subclinical VZV reactivation since that individual had no symptoms of GCA before death and no histopathologic changes of GCA in the TA.
Previous studies to detect VZV in temporal artery biopsies. In earlier studies that examined FFPE GCA-positive and GCA-negative TAs for VZV, detection of VZV DNA and/or VZV antigen correlated positively with the number of sections examined (table 1) . For example, PCR analyses of FFPE GCA-positive and GCA-negative TA biopsy specimens did not reveal VZV DNA when 1-6 sections per TA were examined. [22] [23] [24] [25] Furthermore, immunohistochemistry with VZV-specific antibodies did not detect VZV antigen when only one section from each TA was analyzed, 22 and no herpesvirus particles were found in 2 sections of each TA examined by TEM. 26 In contrast, examination of 4-6 sections detected VZV DNA in 9/35 (26%) GCA-positive TAs, 26 and examination of 10 sections detected VZV DNA in 18/57 (32%) specimens from GCA-positive TAs and 18/56 (32%) from GCA-negative TAs. 27 Furthermore, 25 sections of each FFPE TA biopsy specimen revealed VZV antigen in 5/24 (21%) GCA-negative TAs. 5 While an apparent exception is the detection of VZV antigen in ;50% of GCA-positive and GCAnegative TAs when only one section was studied, 26 sampling was biased since more than half of the TAs were already known to contain VZV DNA. Overall, our detection of VZV antigen in 74% of GCA-positive TAs indicates the value of staining more than 10 sections. In fact, we predict that analysis of hundreds of sections of each TA will reveal VZV in nearly every GCA-positive artery.
Evidence that supports the notion that VZV causes GCA.
VZV is an exclusively human virus that does not produce disease in experimentally infected animals. Nevertheless, multiple findings strongly indicate that VZV is a cause of GCA: (1) VZV was found in 74% of TAs pathologically positive for GCA; (2) despite formalin fixation, VZV DNA was detected in many VZV antigen-positive TAs; (3) VZV antigen and VZV DNA were found in skeletal muscle adjacent to TAs containing VZV; (4) varicella-zoster virions were present in a GCA-positive TA; (5) VZV antigen predominated in the adventitia, indicating that after reactivation from cranial nerve ganglia VZV travels transaxonally to initially infect the arterial adventitia followed by transmural extension; (6) the pathology and distribution of VZV antigen in GCA-positive TAs are virtually identical to those in patients who died of intracerebral VZV vasculopathy; and (7) the presence of VZV antigen was significantly associated with GCA pathology. Because multiple agents underlie other diseases (e.g., pneumonitis and meningitis), it remains possible that agents in addition to VZV cause GCA.
Implications for treatment. The collective findings above directly affect future treatment considerations for patients with GCA. The dramatic favorable response to treatment with corticosteroids in many patients with GCA indicates that the disorder is the result of an inflammatory response to VZV. Many patients require months to years of treatment to fully suppress inflammatory activity. Furthermore, despite corticosteroid therapy, many patients with GCA still experience loss of vision and stroke, 28 and some develop more widespread vasculopathy. 29 A possible explanation for these refractory cases is the long-term potentiation of VZV infection by corticosteroid treatment. Indeed, the apparent role of VZV in triggering the immunopathology of GCA warrants addition of antiviral treatment to corticosteroids. Because GCA seems to be a VZV vasculopathy primarily affecting the TA, treatment of GCA patients with corticosteroids and IV acyclovir, as recommended for intracerebral VZV vasculopathy, is likely to be the most effective therapy and may shorten the length of treatment with corticosteroids. It remains unclear whether standard oral antiviral agents (e.g., valacyclovir, 1 g, 3 times daily for 2-4 weeks) in conjunction with corticosteroids will be as effective as IV acyclovir and corticosteroids; dosage and duration of treatment also remain to be determined.
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